NCT02139163

Brief Summary

The main objective of this study is to investigate prevalence and risk factors for community-acquired pneumonia (CAP) and its interaction with comorbidities in an unselected group of adult patients receiving outpatient and inpatient care. In addition, information on HIV as a risk factor for CAP and on CAP in immunocompromised patients is collected.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20,000

participants targeted

Target at P75+ for all trials

Timeline
26mo left

Started Oct 2002

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Oct 2002Jun 2028

Study Start

First participant enrolled

October 1, 2002

Completed
11.3 years until next milestone

First Submitted

Initial submission to the registry

January 24, 2014

Completed
4 months until next milestone

First Posted

Study publicly available on registry

May 15, 2014

Completed
13.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2027

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2028

Last Updated

May 5, 2026

Status Verified

April 1, 2026

Enrollment Period

25.2 years

First QC Date

January 24, 2014

Last Update Submit

April 29, 2026

Conditions

Community Acquired Pneumonia

Keywords

Community acquired pneumoniaCAPCAPNETZage ≥18infiltrate on chest X-raycough or production of purulent sputumpathologic lung auscultationfeveradults

Outcome Measures

Primary Outcomes (3)

  • diagnosis

    Assessment of diagnosis: Patients will be asked for example, about their diagnosis, comorbidities, specific risk factors and pneumonia symptoms.

    2 weeks

  • therapy

    Assessment of therapy: Patients will be asked about their therapy due to pneumonia symptoms, previous therapy, medication History etc.

    2 weeks

  • hospitalization

    Assessment of hospitalization: Patients will be asked about hospitalization, date, time and duration of hospitalization due to pneumonia symptoms.

    2 weeks

Study Arms (3)

patients with pneumonia

patients with CAP and HIV

immunosuppressed patients with CAP

Interventions

Cohort Study

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with pneumonia

You may qualify if:

  • age ≥ 18
  • infiltrate on chest X-ray

You may not qualify if:

  • Hospitalization lasting longer than 48 hours prior to the diagnosis of the current pneumonia
  • Newly diagnosed, active pulmonary tuberculosis within the last 2 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical School Hannover

Hanover, 30625, Germany

RECRUITING

Related Publications (16)

  • Welte T, Suttorp N, Marre R. CAPNETZ-community-acquired pneumonia competence network. Infection. 2004 Aug;32(4):234-8. doi: 10.1007/s15010-004-3107-z. No abstract available.

    PMID: 15293080BACKGROUND

  • Welte T, Marre R, Suttorp N. [CAPNet--network of competence for community acquired pneumonia: structures and aims]. Pneumologie. 2003 Jan;57(1):34-41. doi: 10.1055/s-2003-36635. German.

    PMID: 12528066BACKGROUND

  • Weckler BC, Wu Q, Bertrams W, Kutzinski M, Reiter R, Khan SA, Ahnert P, Suttorp N, Witzenrath M, Wildberg C, Pletz MW, Rupp J, Zissler UM, Greulich T, Brenner T, Alter P, Rohde G, Vogelmeier CF, Mayr A, Schmeck B. Admission Eosinophil Count Is Associated with Hospital Resource Utilization in Community-Acquired Pneumonia: A Prospective Multicenter Study. Chest. 2026 Mar 31:S0012-3692(26)00427-7. doi: 10.1016/j.chest.2026.03.018. Online ahead of print.

    PMID: 41933608RESULT

  • Mendez R, Gonzalez-Jimenez P, Latorre A, Piqueras M, Mengot N, Hervas D, Knox D, Carr J, Barten-Neiner G, Rohde G, Pletz MW, Rupp J, Witzenrath M, Dean NC, Menendez R. The Long-term Pneumonia Mortality Index. An International Multicenter Derivation and Validation Study for Patients with Community-Acquired Pneumonia. Am J Respir Crit Care Med. 2026 Feb 21:aamag060. doi: 10.1093/ajrccm/aamag060. Online ahead of print.

    PMID: 41738235RESULT

  • Millet Pascual-Leone B, Fiocca Vernengo F, Hillus D, Wernicke C, Krishnamoorthy G, Rupp J, Rohde G, Pletz MW, Witzenrath M; CAPNETZ-study group; Suttorp N, Sander LE, Vestergaard Jensen A, Opitz B, Thibeault C. Community-acquired pneumonia in diabetic patients is characterised by a distinct pathogen spectrum and enhanced inflammation: results from CAPNETZ, a prospective observational cohort study. Infection. 2026 Feb;54(1):275-285. doi: 10.1007/s15010-025-02659-w. Epub 2025 Oct 12.

    PMID: 41077620RESULT

  • Pott H, Gaffron S, Martin R, Maier D, Kutzinski M, Weckler B, Bertrams W, Jung AL, Laakmann K, Heider D, Vogelmeier CF, Rohde G; CAPNETZ Study Group; Schmeck B. Self-organising map clustering identifies high-risk clusters of post-acute mortality in a prospective multicentre study of community-acquired pneumonia. ERJ Open Res. 2026 Jan 19;12(1):00374-2025. doi: 10.1183/23120541.00374-2025. eCollection 2026 Jan.

    PMID: 41561102RESULT

  • Waldeck F, Lemmel S, Panning M, Kading N, Essig A, Rohde G, Pletz MW, Witzenrath M, Boutin S, Rupp J; Members of the CAPNETZ study group. Comparing viral, bacterial, and coinfections in community-acquired pneumonia, a retrospective cohort study. Int J Infect Dis. 2025 May;154:107841. doi: 10.1016/j.ijid.2025.107841. Epub 2025 Feb 21.

    PMID: 39988242RESULT

  • Rischke S, Gurke R, Zielbauer AS, Ziegler N, Hahnefeld L, Kohm M, Kannt A, Vehreschild MJ, Geisslinger G, Rohde G, Bellinghausen C, Behrens F, Study Group C. Proteomic, metabolomic and lipidomic profiles in community acquired pneumonia for differentiating viral and bacterial infections. Sci Rep. 2025 Jan 14;15(1):1922. doi: 10.1038/s41598-025-85229-2.

    PMID: 39809876RESULT

  • Dahne T, Bauer W, Essig A, Schaaf B, Barten-Neiner G, Spinner CD, Pletz MW, Rohde G, Rupp J, Witzenrath M, Panning M; Members of the CAPNETZ study group. Resurgence of common respiratory viruses in patients with community-acquired pneumonia (CAP)-A prospective multicenter study. J Clin Virol. 2024 Aug;173:105694. doi: 10.1016/j.jcv.2024.105694. Epub 2024 May 22.

    PMID: 38781632RESULT

  • Schleenvoigt BT, Ankert J, Barten-Neiner G, Voit F, Suttorp N, Boesecke C, Hoffmann C, Stolz D, Pletz MW, Rohde G, Witzenrath M, Panning M, Essig A, Rupp J, Degen O, Stephan C; CAPNETZ Study Group. Pathogen spectrum of community acquired pneumonia in people living with HIV (PLWH) in the German CAPNETZ-Cohort. Infection. 2024 Feb;52(1):129-137. doi: 10.1007/s15010-023-02070-3. Epub 2023 Jul 9.

    PMID: 37423969RESULT

  • Bahrs C, Kesselmeier M, Kolditz M, Ewig S, Rohde G, Barten-Neiner G, Rupp J, Witzenrath M, Welte T, Pletz MW; CAPNETZ Study Group. A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany. Eur Respir J. 2022 Feb 3;59(2):2102432. doi: 10.1183/13993003.02432-2021. Print 2022 Feb.

    PMID: 34824055RESULT

  • Ewig S, Kolditz M, Pletz M, Altiner A, Albrich W, Dromann D, Flick H, Gatermann S, Kruger S, Nehls W, Panning M, Rademacher J, Rohde G, Rupp J, Schaaf B, Heppner HJ, Krause R, Ott S, Welte T, Witzenrath M. [Management of Adult Community-Acquired Pneumonia and Prevention - Update 2021 - Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Medical Intensive Care and Emergency Medicine (DGIIN), the German Viological Society (DGV), the Competence Network CAPNETZ, the German College of General Practitioneers and Family Physicians (DEGAM), the German Society for Geriatric Medicine (DGG), the German Palliative Society (DGP), the Austrian Society of Pneumology Society (OGP), the Austrian Society for Infectious and Tropical Diseases (OGIT), the Swiss Respiratory Society (SGP) and the Swiss Society for Infectious Diseases Society (SSI)]. Pneumologie. 2021 Sep;75(9):665-729. doi: 10.1055/a-1497-0693. Epub 2021 Jul 1. German.

    PMID: 34198346RESULT

  • Jensen AV, Baunbaek Egelund G, Bang Andersen S, Petersen PT, Benfield T, Witzenrath M, Rohde G, Ravn P, Faurholt-Jepsen D; Members of the CAPNETZ study group except the authors:. The Glycemic Gap and 90-Day Mortality in Community-acquired Pneumonia. A Prospective Cohort Study. Ann Am Thorac Soc. 2019 Dec;16(12):1518-1526. doi: 10.1513/AnnalsATS.201901-007OC.

    PMID: 31437014RESULT

  • Kolditz M, Scherag A, Rohde G, Ewig S, Welte T, Pletz M; CAPNETZ Study Group. Comparison of the qSOFA and CRB-65 for risk prediction in patients with community-acquired pneumonia. Intensive Care Med. 2016 Dec;42(12):2108-2110. doi: 10.1007/s00134-016-4517-y. Epub 2016 Sep 19. No abstract available.

    PMID: 27647332RESULT

  • Kolditz M, Ewig S, Schutte H, Suttorp N, Welte T, Rohde G; CAPNETZ study group. Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med. 2015 Aug;278(2):193-202. doi: 10.1111/joim.12349. Epub 2015 Feb 13.

    PMID: 25597400RESULT

  • Glockner V, Pletz MW, Rohde G, Rupp J, Witzenrath M, Barten-Neiner G, Kolditz M; CAPNETZ Study Group. Early post-discharge mortality in CAP: frequency, risk factors and a prediction tool. Eur J Clin Microbiol Infect Dis. 2022 Apr;41(4):621-630. doi: 10.1007/s10096-022-04416-5. Epub 2022 Feb 8.

    PMID: 35137301DERIVED

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Blood: EDTA whole blood, RNA whole blood, serum, plasma Respiratory: Nasopharyngeal swab, sputum, BAL Urine

MeSH Terms

Conditions

Community-Acquired PneumoniaCoughFever

Condition Hierarchy (Ancestors)

Community-Acquired InfectionsInfectionsPneumoniaRespiratory Tract InfectionsRespiratory Tract DiseasesRespiration DisordersSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsBody Temperature Changes

Study Officials

  • Gernot G. U. Rohde, Prof. Dr.

    University Hospital Giessen and Marburg

    STUDY CHAIR

  • Mathias W. R. Pletz, Prof. Dr.

    University Hospital Jena

    STUDY CHAIR

  • Jan Rupp, Prof. Dr.

    University Hospital Schleswig-Holstein

    STUDY CHAIR

  • Martin Witzenrath, Prof. Dr.

    Charité - Universitaetsmedizin Berlin

    STUDY CHAIR

  • Jessica Rademacher, Prof. Dr.

    Medical School Hannover

    STUDY CHAIR

  • Grit Barten-Neiner

    Capnetz Stiftung

    STUDY CHAIR

Central Study Contacts

Frank Eberhardt

CONTACT

+49-511-532-5927office@capnetz.de

Waldemar Kröner

CONTACT

+49-511-532-4447office@capnetz.de

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 24, 2014

First Posted

May 15, 2014

Study Start

October 1, 2002

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

June 1, 2028

Last Updated

May 5, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

All individual non-personal data and biomaterials collected as part of the study are available for use. This requires a formal request that describes a specific research project and specifies the data needed. Applications have to be submitted on https://capnetz.de/en/project-application/ . Upon approval by the Executive Board, the relevant data and biomaterials will be provided.

Locations

DE(1)